To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

CarMollNat Muscular Dystrophy Endowment

Carol-Ann Harris has established the CarMollNat Endowment in memory of her beloved family members. The Endowment is committed to support research and science for the major forms of Muscular Dystrophy (MD) and neurogenetic disease.

Deeda Blair Research Initiative for Disorders of the Brain

The Deeda Blair Research Initiative for Disorders of the Brain was established by FNIH Board member, Deeda Blair to create hope for millions of people who struggle with mental illness by transforming our existing knowledge of the brain and fostering the development of novel ways of thinking about the brain and its disorders. This initiative will allow forward-thinking scientists to accelerate advances in the diagnosis and treatment of mental health illness including anxiety, depression, bipolar disorder and other serious mood disorders.

Biomarkers Consortium - Neuroscience Symposium

The Neuroscience Steering Committee, led by the FNIH and its co-chairs Dr. Linda Brady, Dr. Hartmuth Kolb, and the emeritus co-chair Dr. Bill Potter, is bringing together experts in the field of neuroscience from industry, NIH, FDA, and academia to present progress to date, next steps, and key obstacles that need to be addressed in order to drive biomarker development in a multitude of neuroscience focus areas. 

Biomarkers Consortium - Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s Plasma Abeta project will evaluate next generation plasma Aβ assays to determine whether plasma Aβ peptide ratios increase the probability of identifying patients with amyloid positivity to improve clinical trial screening efficiency and reduce clinical trial costs for early stages of Alzheimer’s Disease.

2019 Alzheimer's Disease-Related Dementia (ADRD) Summit

The National Institutes of Health (NIH) convened the 3rd Alzheimer's Disease-Related Dementia Summit, that was held on March 14-15, 2019 in Bethesda, Maryland. The 2019 Summit brought together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and NIH to discuss progress made on dementia related research and develop recommendations that will help facilitate new scientific discoveries.

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

2018 Alzheimer’s Disease Research Summit

National Institutes of Health convened the 3rd Alzheimer’s Disease (AD) Research Summit on March 1-2, 2018 in Bethesda, Maryland. The program built on the foundation laid by the 2012 and 2015 NIH AD Research Summits and the U.S. National Alzheimer’s Project Act (NAPA)/National Plan to Address AD.

National Research Summit on Dementia Care: Building Evidence for Services and Supports

On October 16-17, 2017, the National Advisory Council on Alzheimer’s Research, Care and Services held a two-day Summit on the NIH campus entitled: National Research Summit on Dementia Care: Building Evidence for Services and Supports. The purpose of the Summit was to address the growing need for evidence that improves the quality of care and support provided to persons with dementia and their caregivers.

Cognitive Aging Summit III

Held in 2017, the Cognitive Aging Summit III will brought together experts in a variety of research fields to discuss the most cutting edge advances in our understanding of age-related brain and cognitive changes, with a particular focus on resilience and reserve.

2016 Alzheimer's Disease-Related Dementias (ADRD) Summit

The 2016 Alzheimer’s Disease-Related Dementias (ADRD) Summit was hosted by the National Institute of Neurological Disorders and Stroke (NINDS) in collaboration with the National Institute on Aging (NIA) and held March 29-30, 2016 at the Natcher Auditorium on the NIH Campus.